We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Chimeracom Receives Patent for Method of Transporting Pharmacologically Active Peptides Across Blood Brain Barrier

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Chimeracom L.L.C. has announced that the US Patent and Trademark Office issued a US patent for the invention by Chimeracom’s Chief Science Officer, Dr. Richard M. Kream, of a novel method for managing a critical problem in the design of pharmaceuticals.

As Dr. Kream explained, “the blood-brain barrier protects the brain from chemicals in the blood. This barrier must be overcome to deliver potentially important therapeutic and diagnostic agents to the brain. Our patent covers a family of new drugs for the delivery of pharmacologically active peptides into the brain.”

This patent emerged from Chimeracom’s research and development of analgesic drugs. The new US Patent is no. 7,214,657, entitled Method of Transporting a Chimeric Hybrid Molecule Across the Blood Brain Barrier.